PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would resul...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Discov
Asıl Yazarlar: Ibrahim, Yasir H., García-García, Celina, Serra, Violeta, He, Lei, Torres-Lockhart, Kristine, Prat, Aleix, Anton, Pilar, Cozar, Patricia, Guzmán, Marta, Grueso, Judit, Rodríguez, Olga, Calvo, Maria Teresa, Aura, Claudia, Díez, Orland, Rubio, Isabel T., Pérez, José, Rodón, Jordi, Cortés, Javier, Ellisen, Leif W., Scaltriti, Maurizio, Baselga, José
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5125254/
https://ncbi.nlm.nih.gov/pubmed/22915752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0348
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller